Literature DB >> 15584926

Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release.

Matteo Marti1, Flora Mela, Remo Guerrini, Girolamo Calò, Clementina Bianchi, Michele Morari.   

Abstract

We recently showed that pharmacological blockade of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptors located in the substantia nigra stimulates the nigrostriatal dopaminergic pathway and motor behavior (Marti et al. J. Neurosci. 2004, 24, 6659-6666). To investigate whether such motor-stimulating action was dependent on functional dopaminergic transmission, the selective NOP receptor peptide antagonist [Nphe1,Arg14,Lys15]N/OFQ-NH2 (UFP-101) was microinjected into the substantia nigra reticulata of rats made cataleptic by systemic haloperidol administration. UFP-101 reduced haloperidol-induced akinesia as measured by immobility time in the bar test. UFP-101 also induced contralateral turning in cataleptic rats. To investigate the mechanisms involved in the anti-akinetic action of UFP-101, nigral glutamate release was monitored by microdialysis technique. The anti-akinetic action of UFP-101 correlated with normalization of nigral glutamate release, previously elevated by haloperidol injection. We conclude that endogenous N/OFQ in the substantia nigra sustains akinesia generated by impaired DA transmission and subthalamic nucleus overactivation. NOP receptor antagonists may be beneficial in the symptomatic therapy of parkinsonism, via normalization of subthalamonigral glutamatergic transmission.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15584926     DOI: 10.1111/j.1471-4159.2004.02843.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  12 in total

1.  Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.

Authors:  Ludovico Arcuri; Salvatore Novello; Martina Frassineti; Daniela Mercatelli; Clarissa Anna Pisanò; Ilaria Morella; Stefania Fasano; Blair V Journigan; Michael E Meyer; Willma E Polgar; Riccardo Brambilla; Nurulain T Zaveri; Michele Morari
Journal:  Br J Pharmacol       Date:  2018-01-31       Impact factor: 8.739

Review 2.  Managing Parkinson's disease: moving ON with NOP.

Authors:  Daniela Mercatelli; Erwan Bezard; Roberto Eleopra; Nurulain T Zaveri; Michele Morari
Journal:  Br J Pharmacol       Date:  2020-01-03       Impact factor: 8.739

3.  Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.

Authors:  M Marti; F Mela; M Budri; M Volta; D Malfacini; S Molinari; N T Zaveri; S Ronzoni; P Petrillo; G Calò; M Morari
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

Review 4.  UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.

Authors:  Girolamo Calo'; Anna Rizzi; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura; Domenico Regoli; Maurizio Massi; Severo Salvadori; David G Lambert; Remo Guerrini
Journal:  CNS Neurosci Ther       Date:  2010-05-18       Impact factor: 5.243

5.  MPTP treatment increases expression of pre-pro-nociceptin/orphanin FQ mRNA in a subset of substantia nigra reticulata neurons.

Authors:  S Gouty; J M Brown; J Rosenberger; B M Cox
Journal:  Neuroscience       Date:  2010-04-22       Impact factor: 3.590

6.  Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies.

Authors:  Isabella Canazza; Andrea Ossato; Claudio Trapella; Anna Fantinati; Maria Antonietta De Luca; Giulia Margiani; Fabrizio Vincenzi; Claudia Rimondo; Fabiana Di Rosa; Adolfo Gregori; Katia Varani; Pier Andrea Borea; Giovanni Serpelloni; Matteo Marti
Journal:  Psychopharmacology (Berl)       Date:  2016-08-15       Impact factor: 4.530

Review 7.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

8.  Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism.

Authors:  Riccardo Viaro; Rosario Sanchez-Pernaute; Matteo Marti; Claudio Trapella; Ole Isacson; Michele Morari
Journal:  Neurobiol Dis       Date:  2008-03-08       Impact factor: 5.996

9.  Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.

Authors:  Ludovico Arcuri; Riccardo Viaro; Simone Bido; Francesco Longo; Mariangela Calcagno; Pierre-Olivier Fernagut; Nurulain T Zaveri; Girolamo Calò; Erwan Bezard; Michele Morari
Journal:  Neurobiol Dis       Date:  2016-01-22       Impact factor: 5.996

10.  Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats.

Authors:  Manuela Di Benedetto; Chiara Cavina; Claudio D'Addario; Giorgia Leoni; Sanzio Candeletti; Brian M Cox; Patrizia Romualdi
Journal:  Neuropharmacology       Date:  2009-03       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.